The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info‚ÄĒit‚Äôs all here.

Press Release

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

A close up of a cell in the air.
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. These oncology experts are among the country‚Äôs preeminent leaders in cancer biology and clinical care and join the company‚Äôs existing advisors who hail from top cancer research institutions and facilities collaborating with Calidi in the development of its novel immunotherapies targeting high-grade gliomas and solid tumors.

January 8, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi‚Äôs NeuroNova (NNV) and SuperNova (SNV) allogeneic stem cell-based virotherapy platforms at the upcoming 8th Oncolytic Virotherapy Summit to be held December 12-14, 2023 in Boston, Mass.

December 13, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPr√© to the company‚Äôs Board of Directors effective January 1, 2024

December 12, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company‚Äôs SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.

November 20, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

November 14, 2023
Discover More
Discover More
Discover More
Press Release

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. These oncology experts are among the country‚Äôs preeminent leaders in cancer biology and clinical care and join the company‚Äôs existing advisors who hail from top cancer research institutions and facilities collaborating with Calidi in the development of its novel immunotherapies targeting high-grade gliomas and solid tumors.

January 8, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi‚Äôs NeuroNova (NNV) and SuperNova (SNV) allogeneic stem cell-based virotherapy platforms at the upcoming 8th Oncolytic Virotherapy Summit to be held December 12-14, 2023 in Boston, Mass.

December 13, 2023
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPr√© to the company‚Äôs Board of Directors effective January 1, 2024

December 12, 2023
Discover More
Press Release

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company‚Äôs SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.

November 20, 2023
Discover More
Press Release

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

November 14, 2023
Discover More
Publication
event
NeuroNova
Supernova

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

The Journal of Translational Medicine

May 18, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

Abstract 21: A cell-based platform to potentiate oncolytic virus therapies

February 6, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

Journal of Clinical Oncology

February 4, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Discover More
Publication
event
NeuroNova
Supernova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019
Discover More
Discover More
Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024
Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024
Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024
Media

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

February 3, 2024
Media

Executive Interview: Allan Camaisa (CEO)

February 2, 2024
Media

Executive Interview: Stephen Thesing (CBO)

February 2, 2024
In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023
Discover More
Discover More
In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023
Discover More
Discover More

All Courses

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more